|
| Status |
Public on Jul 01, 2011 |
| Title |
Control 4 |
| Sample type |
RNA |
| |
|
| Source name |
peripheral blood mononuclear cells
|
| Organism |
Homo sapiens |
| Characteristics |
cell type: peripheral blood mononuclear
disease state: healthy
|
| Treatment protocol |
Peripheral blood mononuclear cells were isolated from whole blood using BD Vacutainer® CPT™ Cell Preparation Tubes (Becton, Dickinson and Company, NJ, USA) according to the manufacturer's recommendations. Cells were homogenized in TRIzol® (Invitrogen, CA, US) and samples were stored in -80°C until RNA isolation.
|
| Extracted molecule |
total RNA |
| Extraction protocol |
RNA was extracted with RNeasy Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions.
|
| Label |
biotin
|
| Label protocol |
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 1-2 ug total RNA (GeneChip Expression Analysis Technical Manual, 2005-2006, Affymetrix).
|
| |
|
| Hybridization protocol |
Following fragmentation, 15 ug of cRNA were hybridized for 16 hr at 45C on GeneChip® Human Genome U133 Plus 2.0 Array for 16 hours at 45°C and washed and stained in the Affymetrix Fluidics Station 450.
|
| Scan protocol |
GeneChips were scanned using the Affymetrix GeneChip Scanner 3000.
|
| Description |
Gene expression data from controls representing the general population.
|
| Data processing |
The data were GC-RMA normalized and analyzed with GeneSpring 7.3 GX (Agilent Technologies, CA, US). After normalization and data filtering MS_11_REPL2 and MS_12_REPL2 were excluded from analysis.
|
| |
|
| Submission date |
May 20, 2010 |
| Last update date |
Jul 01, 2011 |
| Contact name |
Anu Kemppinen |
| E-mail(s) |
[email protected]
|
| Organization name |
University of Cambridge
|
| Street address |
Addenbrooke's Hospital, Hills Road
|
| City |
Cambridge |
| ZIP/Postal code |
CB2 0QQ |
| Country |
United Kingdom |
| |
|
| Platform ID |
GPL570 |
| Series (1) |
| GSE21942 |
Expression data from peripheral blood mononuclear cells in multiple sclerosis patients and controls |
|
